Editor's Choice
Main Category: HIV / AIDS
Also Included In: Aid / Disasters
Article Date: 16 May 2012 - 14:00 PDT
Patient / Public:
Healthcare Prof:
The May 16 edition of the Global Health themed issue of JAMA reveals a larger drop in all-cause adult mortality in those African countries with more intense operation of the AIDS relief program PEPFAR.
The article's background information states:
"The effect of global health initiatives on population health is uncertain. Between 2003 and 2008, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), the largest initiative ever devoted to a single disease, operated intensively in 12 African focus countries."
PEPFAR has undertaken a coordinated effort to raise treatment, prevention and care of HIV and increased the delivery of expanded antiretroviral therapy (ART) supporting wide-scale prevention efforts in view of the rapidly increasing HIV epidemic.
Eran Bendavid, M.D., M.S., from California's Stanford University, and his team decided to assess the association between PEPFAR's implementation and trends in adult mortality given that the initiative's impact on all-cause adult mortality is not known.
The team used person-level data from the Demographic and Health Surveys (DHS) to conduct cross-country and within-country analyses of adult mortality defined as the annual probability of death per 1,000 adults between the ages of 15 to 59 years old, and PEPFAR activities. They then compared the adult mortality across 9 African 'focus countries', including Ethiopia, Kenya, Mozambique, Namibia, Nigeria, Rwanda, Tanzania, Uganda and Zambia with the adult mortality in 18 African 'non-focus countries' for the duration of one decade, from 1998 to 2008.
The study included data from 41 surveys across 27 countries, between 1998 and 2008, on 1,538,612 African adults. The DHS registered 60,303 deaths during this time period that were included in this study.
A data analysis showed a relatively larger decline in death rates amongst adults in focus countries between 2004 and 2008, namely a decrease from 8.30 per 1,000 adults in 2003 to 4.10 per 1,000 in 2008, whilst the mortality rate in non-focus countries dropped from 8.5 in 2003 to 6.9 in 2008 during the study period.
After adjusting for variables, such as country-level and personal characteristics, the likelihood of all-cause mortality was lower in the focus countries than in the non-focus countries.
The team also analyzed district-level data for Tanzania and Rwanda and even though high and low PEPFAR activity districts counted similar populations, the program intensity was considerably different between both groups. The findings revealed that Tanzanian adults living in regions with above-midpoint PEPFAR intensity had a lower risk of mortality than adults living in regions with below-midpoint intensity, whilst the comparison amongst Rwandan adults was similar, with a lower death risk for adults living in regions with above-midpoint PEPFAR intensity.
The researchers also discovered that a total of 740,914 all-cause adult deaths were averted between 2004 and 2008, due to PEPFAR's efforts.
The figure was calculated by using the results of each focus country and generalizing it to the size of each country's adult population. In comparison, PEPFAR was linked to an estimated number of 631,338 averted HIV-specific deaths during the same period.
The researchers write:
"In conclusion, we provide new evidence suggesting that reductions in all- cause adult mortality were greater in PEPFAR's focus countries relative to the non-focus countries over the time period from 2004 through 2008. Our analysis suggests an association of PEPFAR with these improvements in population health."
Editorial: PEPFAR and Maximizing the Effects of Global Health Assistance
Ezekiel J. Emanuel, M.D., Ph.D., of the University of Pennsylvania in Philadelphia writes in an associated editorial, the "article by Bendavid et al is welcome news in helping to document the even greater benefits of PEPFAR not only on HIV/AIDS but on overall mortality in countries. However, the further question that must be asked by ethically responsible people and policy makers becomes: Is PEPFAR worth it? Many other global health programs are improving the health of poor people worldwide but are not funded anywhere near the level of PEPFAR. The fundamental ethical, economic, and policy question is not whether PEPFAR is doing good, but rather whether other programs would do even more good in terms of saving life and improving health. Clearly, besides treatment for HIV/AIDS, there are other highly effective and lower-cost interventions for the world's poor." Written By Petra Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
- Additional
- References
- Citations
Eran Bendavid, MD, MS; Charles B. Holmes, MD, MPH; Jay Bhattacharya, MD, PhD; and Grant Miller, PhD, MP
JAMA , May 2012, doi:10.1001/jama.2012.2001 Please use one of the following formats to cite this article in your essay, paper or report:
MLA
APA
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'AIDS Relief Program Intensity Linked To Lower Death Rates'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy | Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.
back to top | home | privacy policy
MediLexicon International LtdBexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
MNT (logo) is the registered EU trade mark of MediLexicon Int. Limited.
Tidak ada komentar:
Posting Komentar